| Patient | Franklin D. Roosevelt |
|---|---|
| Date of birth | 1964-01-30 |
| Identifiers | MRN HR-ET002-SYN; SSN (made up) 000-02-5130 |
| Document date | 2026-09-25 |
| Author | Nathaniel Brooks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month heart failure review with repeat echocardiogram. [S]
Mr. Roosevelt returns for his six-month review and repeat echocardiogram. The stomach illness in July settled within four days; he restarted his heart failure medicines on the third day without lightheadedness, and his weight is back to 82 kg. He is finishing an adapted cardiac rehabilitation program of seated arm-cycle and resistance-band training and will keep up the band exercises at home three times a week. He propels his wheelchair on level ground and up short ramps without breathlessness, sleeps on one pillow, and has had no leg swelling since furosemide stopped. His home blood pressures run 115 to 125 systolic, and he has had no lightheadedness on transfers. He has not smoked since April. He prefers not to raise his medicine doses further for now, because safe transfers matter more to him than small further gains, and the July illness showed how quickly his blood pressure can fall. [S]
| Element | Detail |
|---|---|
| Interval change | July gastroenteritis resolved in four days; medicines restarted on the third day |
| Function | Level ground and short ramps without breathlessness; finishing cardiac rehabilitation |
| Weight log | Back to 82 kg; no swelling off furosemide |
| Home blood pressure | 115 to 125 systolic |
| Tobacco | No cigarettes since April |
| Patient preference | No further dose increases for now, to protect safe transfers |
| NYHA class | I to II |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Good energy; weight stable |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or leg swelling |
| Respiratory | Negative | No breathlessness on level ground or short ramps |
| Gastrointestinal | Negative | Bowel habit back to his usual since July |
| Neurological | Negative | No lightheadedness on transfers |
| Musculoskeletal | Negative | No muscle aches; no shoulder pain with rehabilitation exercise |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2026-03-27 to 2026-04-10 | completed | S |
| Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2026-04-10 | active | S |
| Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 2026-03-27 to 2026-04-10 | completed | S |
| Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 2026-04-10 to 2026-06-26 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 2026-06-26 | active | S |
| Spironolactone 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-10 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 | active | S |
| Furosemide 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 to 2026-06-26 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-27 | active | S |
| Nicotine 21 mg/24 hr transdermal patch, apply one patch daily | Apply one patch to the skin daily | Topical route | 2026-03-27 to 2026-06-26 | completed | S |
| Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart | 750 mg intravenously, two doses one week apart | Intravenous route | 2026-04-10 to 2026-04-17 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-25 | Body height | 188 | cm | S |
| 2026-09-25 | Body weight | 82 | kg | S |
| 2026-09-25 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-09-25 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-25 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-25 | Heart rate | 64 | /min | S |
| 2026-09-25 | Respiratory rate | 14 | /min | S |
| 2026-09-25 | Body temperature | 36.7 | Cel | S |
| 2026-09-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-25 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 410 | pg/mL | <=125 pg/mL | High | S |
| 2026-09-25 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-25 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-25 | Creatinine [Mass/volume] in Serum or Plasma | 1.21 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-25 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 68 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-25 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-25 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-09-25 | Albumin/Creatinine [Mass Ratio] in Urine | 22 | mg/g | <=30 mg/g | Normal | S |
| 2026-09-25 | Left ventricular Ejection fraction | 45 | % | 50-70% | Low | S |
| 2026-09-25 | Overall summary score [KCCQ-12] | 78 | {score} | S |
Vital signs recorded on 2026-09-25; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 82 kg on the wheelchair scale |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm, rate 64; no S3 |
| Extremities | No edema; dorsalis pedis and posterior tibial pulses palpable in both feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findings | active | confirmed | I11.0 | S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D. |
| Heart failure with reduced ejection fraction, NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic diagnosis confirmed by echocardiogram in the modern episode. |
| Nicotine dependence, cigarettes | active | confirmed | F17.210 | S — Synthetic modern diagnosis linked to documented cigarette smoking. |
| Iron deficiency anemia in heart failure, repleted with intravenous iron | resolved | confirmed | D50.9 | S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S. |
| Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed | active | provisional | B91 | S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R. |
| Prediabetes | active | confirmed | R73.03 | S — Synthetic finding from the baseline HbA1c. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| Acute viral gastroenteritis with mild volume depletion, resolved with oral rehydration and a short hold of heart failure medicines | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | Every 3 to 6 months when stable | Completed today | Potassium 4.5, creatinine 1.21 mg/dL, eGFR 68; back to baseline after creatinine 1.42 at the July sick visit |
| Laboratory | Basic metabolic panel after stopping furosemide in June | 1 to 2 weeks after a diuretic change | Deferred | Not drawn in the window, a deviation from the protocol. The next panel was at the July sick visit, about four and a half weeks later, with potassium 4.9 during volume depletion; today's potassium is 4.5, so no harm resulted. This is the second missed post-change check this year; the corrective action is the dated laboratory appointment at every medication change |
| Laboratory | Basic metabolic panel after restarting the medicines held in July | 1 to 2 weeks after restarting sacubitril/valsartan, spironolactone, and empagliflozin | Deferred | The sick-visit plan moved the recheck to today; strictly, the protocol calls for a panel within two weeks of a restart, so this is recorded as a deviation. Today's potassium and creatinine are at baseline, so no harm resulted. Corrective action: a panel one to two weeks after any future sick-day restart |
| Laboratory | Magnesium | With each basic metabolic panel | Deferred | Not measured with any panel since diagnosis, a deviation from the protocol. He has had no arrhythmia or cramps and has been off the loop diuretic since June, so the risk of low magnesium is small. Corrective action: added to the three-month panel |
| Laboratory | NT-proBNP | Selectively in outpatient follow-up | Completed today | 410 pg/mL, down from 2850; supports prognosis and decongestion |
| Imaging | Transthoracic echocardiogram | 3 to 6 months after therapy is optimized | Completed today | Ejection fraction 45 percent, up from 30: heart failure with improved ejection fraction. No device therapy is indicated, and routine repeat imaging is not recommended |
| Imaging | 12-lead ECG | At initial evaluation; repeat with device consideration | Deferred | Still not on file, a deviation carried from April. No device decision is needed now that the ejection fraction is 45 percent, and his rhythm is regular, so no harm has resulted. Corrective action: ECG at the three-month review |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit; every 3 to 6 months when stable | Completed today | Euvolemic at 82 kg |
| Survey | NYHA functional class | Every visit | Completed today | Class I to II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 78, up 40 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Due | Score 0 in June; repeat at next month's preventive visit |
| Referral | Cardiac rehabilitation | Periodic review of participation and exercise capacity | Up to date | Finishing the adapted program; home resistance-band exercise three times a week to follow |
| Medication safety | Dose review of guideline-directed therapy | Each visit while titrating | Completed today | Sacubitril/valsartan and carvedilol remain below target doses by shared decision, to protect transfer safety; revisit at the three-month review |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin; then yearly | Completed today | LDL cholesterol 68 mg/dL, a 48 percent fall, below 70 mg/dL. Drawn 26 weeks after the start, outside the window (deviation recorded in June); the response is adequate, so no harm resulted |
| Laboratory | Lipoprotein(a) | Once in adulthood | Due | Not yet measured; add to the next laboratory tests |
| Laboratory | Urine albumin-creatinine ratio | Yearly in hypertension | Completed today | 22 mg/g, down from 64; now normal |
| Laboratory | HbA1c for prediabetes | Yearly | Up to date | 5.9 percent at diagnosis; glucose 95 mg/dL today |
| Laboratory | Hemoglobin and iron studies | Yearly in heart failure with reduced or improved ejection fraction | Up to date | Repleted in June |
| Examination | Funduscopic examination | Yearly in chronic hypertension | Due | Last eye examination more than two years ago; to be arranged at next month's preventive visit |
| Examination | Peripheral pulses and ankle-brachial index | Every 2 to 3 years with a smoking history | Due | Foot pulses palpable today; ankle-brachial index not yet done and due within the interval |
| Survey | 10-year ASCVD risk estimate | Yearly in hypertension | Not indicated | Not calculated: he already takes a statin for his LDL cholesterol and hypertensive heart disease, so the estimate would not change treatment |
| Medication safety | Tobacco use | Every visit | Completed today | Abstinent since April |
| Medication safety | Influenza vaccine | Every season | Due | Planned at next month's preventive visit |
| Self-management | Home blood pressure and daily weight log; low-sodium diet | Every visit | Completed today | Log reviewed; weights stable without furosemide |
Goal progress:
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); USPSTF A and B Recommendations (2026)
Follow-up: Preventive visit next month. Heart failure review in three months with a basic metabolic panel with magnesium, an ECG, the KCCQ-12, and a decision on dose increases. Next scheduled visit 2026-10-23: periodic adult preventive visit. [S]